Experiments in sheep are hinting that doses of caffeine given to women in pregnancy, as well as their newborns after birth, ...

Despite being back in the season of sniffles and sick days, Washington state will be extra equipped to battle the spread of respiratory viruses this year.

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

The Eastern Ontario Health Unit (EOHU) is pleased to announce that a new preventive treatment that protects against ...

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

The company’s monoclonal antibody met primary endpoints in Phase IIb/III trial in infants entering their first respiratory ...

(Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory ...

MOBILE, Ala. ( WALA) - At USA Health Children’s & Women’s Hospital, doctors are seeing a rise in pediatric RSV cases. Dr.

What is this silent virus that endangers Filipino Seniors with comorbidities? Respiratory Syncytial Virus (RSV) is not just another cold or flu—it is potentially life- threatening for ...

Coronavirus cases have been rising across the UK for the past few weeks, with the new XEC variant of Covid-19 becoming more ...